JPWO2022038170A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2022038170A5 JPWO2022038170A5 JP2023512063A JP2023512063A JPWO2022038170A5 JP WO2022038170 A5 JPWO2022038170 A5 JP WO2022038170A5 JP 2023512063 A JP2023512063 A JP 2023512063A JP 2023512063 A JP2023512063 A JP 2023512063A JP WO2022038170 A5 JPWO2022038170 A5 JP WO2022038170A5
- Authority
- JP
- Japan
- Prior art keywords
- disorder
- substituted
- compound
- unsubstituted
- deuterium
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025185299A JP2026041715A (ja) | 2020-08-18 | 2025-11-04 | 治療用フェネチルアミン組成物およびその使用方法 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063067303P | 2020-08-18 | 2020-08-18 | |
| US63/067,303 | 2020-08-18 | ||
| US202063131974P | 2020-12-30 | 2020-12-30 | |
| US63/131,974 | 2020-12-30 | ||
| PCT/EP2021/072896 WO2022038170A1 (en) | 2020-08-18 | 2021-08-18 | Therapeutic phenethylamine compositions and methods of use |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025185299A Division JP2026041715A (ja) | 2020-08-18 | 2025-11-04 | 治療用フェネチルアミン組成物およびその使用方法 |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2023540017A JP2023540017A (ja) | 2023-09-21 |
| JP2023540017A5 JP2023540017A5 (https=) | 2024-08-20 |
| JPWO2022038170A5 true JPWO2022038170A5 (https=) | 2024-08-20 |
| JP7802769B2 JP7802769B2 (ja) | 2026-01-20 |
Family
ID=77564095
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023512063A Active JP7802769B2 (ja) | 2020-08-18 | 2021-08-18 | 治療用フェネチルアミン組成物およびその使用方法 |
| JP2023512107A Pending JP2023539113A (ja) | 2020-08-18 | 2021-08-18 | フェネチルアミン誘導体、組成物およびその使用方法 |
| JP2025185299A Pending JP2026041715A (ja) | 2020-08-18 | 2025-11-04 | 治療用フェネチルアミン組成物およびその使用方法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023512107A Pending JP2023539113A (ja) | 2020-08-18 | 2021-08-18 | フェネチルアミン誘導体、組成物およびその使用方法 |
| JP2025185299A Pending JP2026041715A (ja) | 2020-08-18 | 2025-11-04 | 治療用フェネチルアミン組成物およびその使用方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (3) | US12122741B2 (https=) |
| EP (2) | EP4200021A1 (https=) |
| JP (3) | JP7802769B2 (https=) |
| KR (3) | KR20230051486A (https=) |
| AU (2) | AU2021328671A1 (https=) |
| CA (2) | CA3186357A1 (https=) |
| WO (2) | WO2022038171A1 (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PH12022551981A1 (en) | 2020-02-04 | 2023-10-16 | Mindset Pharma Inc | Psilocin derivatives as serotonergic psychedelic agents for the treatment of cns disorders |
| KR20240096817A (ko) | 2020-05-19 | 2024-06-26 | 사이빈 아이알엘 리미티드 | 중수소화된 트립타민 유도체 및 사용 방법 |
| US12122741B2 (en) | 2020-08-18 | 2024-10-22 | Cybin Irl Limited | Therapeutic phenethylamine compositions and methods of use |
| EP4405318A4 (en) * | 2021-09-25 | 2025-11-05 | Alexander Shulgin Res Institute Inc | PHENYLAKYLAMINES SUBSTITUTED |
| WO2023168023A1 (en) | 2022-03-04 | 2023-09-07 | Reset Pharmaceuticals, Inc. | Co-crystals or salts comprising psilocin |
| EP4594297A4 (en) * | 2022-09-26 | 2026-03-04 | Caamtech Inc | 2-(2-ETHOXY-4-(ETHYLTHIO)-5-METHOXYPHENYL)ETHAN-1-AMINIUM CHLORIDE |
| KR20250097837A (ko) * | 2022-10-28 | 2025-06-30 | 사이빈 아이알엘 리미티드 | 펜에틸아민 화합물, 조성물, 및 사용 방법 |
| EP4727538A2 (en) * | 2023-06-15 | 2026-04-22 | Tactogen Inc. | New formulations for mental disorders or mental enhancement |
| WO2025228547A1 (en) | 2024-05-01 | 2025-11-06 | Cybin Irl Limited | Processes for preparing phenethylamine compounds |
Family Cites Families (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4911920A (en) | 1986-07-30 | 1990-03-27 | Alcon Laboratories, Inc. | Sustained release, comfort formulation for glaucoma therapy |
| FR2588189B1 (fr) | 1985-10-03 | 1988-12-02 | Merck Sharp & Dohme | Composition pharmaceutique de type a transition de phase liquide-gel |
| ATE141502T1 (de) | 1991-01-15 | 1996-09-15 | Alcon Lab Inc | Verwendung von karrageenan in topischen ophthalmologischen zusammensetzungen |
| US5212162A (en) | 1991-03-27 | 1993-05-18 | Alcon Laboratories, Inc. | Use of combinations gelling polysaccharides and finely divided drug carrier substrates in topical ophthalmic compositions |
| DE19859684A1 (de) * | 1998-12-23 | 2000-06-29 | Bayer Ag | Verfahren zur Herstellung von Fluor enthaltenden Phenethylaminen sowie neue, Fluor enthalende beta-Iminovinyl- und beta-Iminoethylbenzole |
| JP2002293764A (ja) * | 2001-01-26 | 2002-10-09 | Takeda Chem Ind Ltd | アミノエタノール誘導体 |
| US7267121B2 (en) | 2004-04-20 | 2007-09-11 | Aerogen, Inc. | Aerosol delivery apparatus and method for pressure-assisted breathing systems |
| HN2005000795A (es) * | 2004-10-15 | 2010-08-19 | Aventis Pharma Inc | Pirimidinas como antagonistas del receptor de prostaglandina d2 |
| WO2006079999A2 (en) | 2006-04-09 | 2006-08-03 | Barth Frederik H | Induction of a novel state of mind with a 5-ht2a agonist and a nmda antagonist |
| WO2008016677A2 (en) | 2006-08-02 | 2008-02-07 | Auspex Pharmaceuticals, Inc. | Preparation and utility of deuterated amphetamines |
| CN104906669A (zh) | 2007-03-30 | 2015-09-16 | 菲利普莫里斯生产公司 | 用于输送药剂的装置和方法 |
| WO2016040822A1 (en) * | 2014-09-12 | 2016-03-17 | Pinpoint Testing, Llc | Ready-to-constitute analytical platforms for chemical analyses and quantification |
| PL3625228T3 (pl) * | 2017-05-18 | 2021-12-20 | Idorsia Pharmaceuticals Ltd | Pochodne pirymidyny jako modulatory receptora pge2 |
| EP4353314A3 (en) | 2019-02-22 | 2024-07-03 | GH Research Ireland Limited | 5-methoxy-n,n-dimethyltryptamine (5-meo-dmt) for treating major depression |
| EP4219498A1 (en) | 2019-03-07 | 2023-08-02 | Arbormentis LLC | Compositions and methods of use comprising substances with neural plasticity actions administered at non-psychedelic / psychotomimetic dosages and formulations |
| KR20220009954A (ko) | 2019-04-17 | 2022-01-25 | 컴퍼스 패쓰파인더 리미티드 | 신경인지 장애, 만성 통증을 치료하고 염증을 감소시키는 방법 |
| GB201907871D0 (en) | 2019-06-03 | 2019-07-17 | Small Pharma Ltd | Therapeutic compositions |
| WO2021003467A1 (en) | 2019-07-04 | 2021-01-07 | Sw Holdings, Inc. | Metered dosing compositions and methods of use of psychedelic compounds |
| CN112430187B (zh) | 2019-08-07 | 2023-01-17 | 北京奇点势能科技有限公司 | 一种α,β-氘代胺类化合物、氘代药物及其制备方法 |
| US11246860B2 (en) | 2019-11-07 | 2022-02-15 | Lophora ApS | 5-HT2A agonists for use in treatment of depression |
| WO2021234608A1 (en) | 2020-05-19 | 2021-11-25 | Cybin Irl Limited | Deuterated tryptamine derivatives and methods of use |
| EP3902541B1 (en) | 2020-06-02 | 2022-09-14 | Small Pharma Ltd | Therapeutic compositions comprising deuterated or partially deuterated n,n-dimethyltryptamine compounds |
| RU199823U1 (ru) | 2020-06-10 | 2020-09-21 | Общество С Ограниченной Ответственностью "Центр Передовых Радиационных Медицинских И Биологических Технологий | Устройство для лечения бронхолегочных заболеваний |
| US12122741B2 (en) | 2020-08-18 | 2024-10-22 | Cybin Irl Limited | Therapeutic phenethylamine compositions and methods of use |
| JP2023544724A (ja) | 2020-10-02 | 2023-10-25 | サイビン アイアールエル リミテッド | 吸入による幻覚発動薬の送達方法および方法を実施するためのシステム |
| WO2022182602A2 (en) | 2021-02-24 | 2022-09-01 | Mind Medicine, Inc. | Mescaline derivatives with modified action |
| US20220323378A1 (en) | 2021-04-03 | 2022-10-13 | Shawn Joseph | Pharmaceutical Compositions and Methods for Treating Mental Health Disorders and Promoting Neural Plasticity |
| WO2022221942A1 (en) | 2021-04-19 | 2022-10-27 | Betterlife Pharma Inc. | Prevention of drug diversion |
| WO2022225884A1 (en) | 2021-04-22 | 2022-10-27 | Lennham Pharmaceuticals, Inc. | Deuterated derivatives of psychedelic compounds and uses thereof |
| BR112023025599A2 (pt) | 2021-06-08 | 2024-02-20 | Entheogenix Biosciences Inc | Ativadores de dimetoxifenilalquilamina de receptores de serotonina. |
| WO2022271982A1 (en) | 2021-06-23 | 2022-12-29 | Synaptive Therapeutics, Llc | Substituted phenethylamine for treating inflammation and psychological disorders |
| WO2023283386A2 (en) | 2021-07-07 | 2023-01-12 | Arcadia Medicine, Inc. | Safer psychoactive compositions |
| CA3209813A1 (en) | 2021-07-14 | 2023-01-19 | Mydecine Innovations Group Inc. | Novel short-acting psychoactive compounds of the mdma class |
| CA3229713A1 (en) | 2021-08-20 | 2023-02-23 | Terran Biosciences Inc. | Deuterated analogs and derivatives of 4-bromo-2,5-dimethoxyphenethylamine and uses thereof |
| WO2023036473A1 (en) | 2021-09-08 | 2023-03-16 | Cybin Irl Limited | Combination drug therapies |
| EP4405318A4 (en) | 2021-09-25 | 2025-11-05 | Alexander Shulgin Res Institute Inc | PHENYLAKYLAMINES SUBSTITUTED |
| CA3244130A1 (en) | 2022-02-15 | 2023-08-24 | Cybin Irl Limited | PHENETYLAMINE DERIVATIVES, COMPOSITIONS AND METHODS OF USE |
| KR20240153566A (ko) | 2022-02-15 | 2024-10-23 | 사이빈 아이알엘 리미티드 | 치료적 펜에틸아민 조성물, 및 사용 방법 |
| AU2023242469A1 (en) | 2022-03-31 | 2024-09-05 | Cybin Irl Limited | Combination of nitrous oxide and 5-ht2a receptor agonists |
| AU2023246690A1 (en) | 2022-03-31 | 2024-11-07 | Cybin Irl Limited | Methods for delivery of psychedelic medications by inhalation and systems for performing the methods |
| KR20250097837A (ko) | 2022-10-28 | 2025-06-30 | 사이빈 아이알엘 리미티드 | 펜에틸아민 화합물, 조성물, 및 사용 방법 |
-
2021
- 2021-08-18 US US18/041,731 patent/US12122741B2/en active Active
- 2021-08-18 AU AU2021328671A patent/AU2021328671A1/en active Pending
- 2021-08-18 EP EP21766581.9A patent/EP4200021A1/en active Pending
- 2021-08-18 CA CA3186357A patent/CA3186357A1/en active Pending
- 2021-08-18 EP EP21763068.0A patent/EP4200290A1/en active Pending
- 2021-08-18 KR KR1020237003815A patent/KR20230051486A/ko active Pending
- 2021-08-18 KR KR1020267007984A patent/KR20260044248A/ko active Pending
- 2021-08-18 WO PCT/EP2021/072898 patent/WO2022038171A1/en not_active Ceased
- 2021-08-18 AU AU2021327136A patent/AU2021327136B2/en active Active
- 2021-08-18 JP JP2023512063A patent/JP7802769B2/ja active Active
- 2021-08-18 KR KR1020237006128A patent/KR20230053611A/ko active Pending
- 2021-08-18 US US18/041,728 patent/US20240317704A1/en active Pending
- 2021-08-18 CA CA3186359A patent/CA3186359A1/en active Pending
- 2021-08-18 WO PCT/EP2021/072896 patent/WO2022038170A1/en not_active Ceased
- 2021-08-18 JP JP2023512107A patent/JP2023539113A/ja active Pending
-
2024
- 2024-09-05 US US18/825,122 patent/US20240425451A1/en active Pending
-
2025
- 2025-11-04 JP JP2025185299A patent/JP2026041715A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL297492A (en) | Deuterated tryptamine derivatives and methods of use | |
| JPWO2022038170A5 (https=) | ||
| JPWO2021234608A5 (https=) | ||
| JP2023106403A5 (https=) | ||
| ES2375872T3 (es) | 3-(1,3-benzodioxol-5-il)-6-(4-ciclopropilpiperacin-1-il)-piridacina, sus sales y solvatos, y su uso como antagonista del receptor h3 de la histamina. | |
| JPWO2020245133A5 (https=) | ||
| JP2021519267A5 (https=) | ||
| JP2015501847A5 (https=) | ||
| JP5699156B2 (ja) | （１，１，１，３，３，３−ヘキサフルオロ−２−ヒドロキシプロパン−２−イル）フェニル誘導体、それらの医薬組成物およびアテローム性動脈硬化症の処置のためのそれらの使用 | |
| JPWO2022038171A5 (https=) | ||
| JP2009502963A5 (https=) | ||
| JP2007508360A5 (https=) | ||
| JP2006143749A5 (https=) | ||
| JP2004511556A5 (https=) | ||
| JPH07206818A (ja) | インドリルシクロアルカニルアミン抗偏頭痛剤 | |
| JP2007522135A5 (https=) | ||
| Partyka et al. | The impact of the halogen bonding on D2 and 5-HT1A/5-HT7 receptor activity of azinesulfonamides of 4-[(2-ethyl) piperidinyl-1-yl] phenylpiperazines with antipsychotic and antidepressant properties | |
| JPWO2021030555A5 (https=) | ||
| JP2008531558A5 (https=) | ||
| JPWO2023156453A5 (https=) | ||
| JPWO2023036473A5 (https=) | ||
| JPWO2022243285A5 (https=) | ||
| JP2011528030A5 (https=) | ||
| JPWO2023156450A5 (https=) | ||
| JPWO2020119819A5 (https=) |